Previous 10 | Next 10 |
Heron Therapeutics Announces Appointment of William Forbes, Pharm.D. as Chief Development Officer PR Newswire SAN DIEGO , June 12, 2023 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the live...
2023-06-03 18:15:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2023-05-25 02:30:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2023-05-17 10:03:19 ET Gainers: XBiotech ( XBIT ) +32% . Impel Pharmaceuticals ( IMPL ) +30% . Immutep ( IMMP ) +14% . Corvus Pharmaceuticals ( CRVS ) +13% . Sientra ( SIEN ) +10% . Losers: Intercept Pharmaceuticals ( ICP...
2023-05-12 13:14:08 ET Gainers: GSI Technology ( GSIT ) +149% . ARS Pharmaceuticals ( SPRY ) +80% . Zapp Electric Vehicles Group Limited ( ZAPP ) +42% . AirSculpt Technologies ( AIRS ) +39% . Blue Bird Corporation ( BLBD ) +34% ....
2023-05-12 11:50:49 ET Heron Therapeutics ( NASDAQ: HRTX ) stock fell ~35% on Friday after Q1 2023 results missed estimates. Its Q1 net loss narrowed to -$32.77M, compared to -63.89M in Q1 2022. Net product sales grew 26.2% Y/Y to $29.62M but missed analysts expectat...
2023-05-12 10:03:10 ET Gainers: ARS Pharmaceuticals ( SPRY ) +77% . Dermata Therapeutics ( DRMA ) +63% . AirSculpt Technologies ( AIRS ) +27% . GlycoMimetics ( GLYC ) +14% . BioAtla ( BCAB ) +13% . Losers: Heron Thera...
2023-05-11 22:18:06 ET Heron Therapeutics, Inc. (HRTX) Q1 2023 Earnings Conference Call May 11, 2023 04:30 PM ET Company Participants Craig Collard - Chief Executive Officer David Szekeres - Executive Vice President & Chief Operating Officer Conference Call...
2023-05-11 16:03:42 ET Heron Therapeutics press release ( NASDAQ: HRTX ): Q1 GAAP EPS of -$0.27 misses by $0.07 . Revenue of $29.62M (+26.3% Y/Y) misses by $0.07M . For further details see: Heron Therapeutics GAAP EPS of -$0.27 misses by $0.07, revenue of...
Heron Therapeutics Announces Financial Results for the Three Months Ended March 31, 2023 and Highlights Recent Corporate Updates PR Newswire · Net Product Sales for First Quarter of 2023 Grew 26% to $29.6 million , Compared to First Quarter Net Product Sales in 2022 ...
News, Short Squeeze, Breakout and More Instantly...
Heron Therapeutics Inc. Company Name:
HRTX Stock Symbol:
NASDAQ Market:
Heron Therapeutics Inc. Website:
Heron Therapeutics Announces the Inclusion of ZYNRELEF® as a Qualifying Product Under the Proposed 2025 Non-Opioid Policy for Pain Relief Under the OPPS and the ASC Payment System PR Newswire SAN DIEGO , July 15, 2024 /PRNewswire/ -- Heron Therapeutics, Inc....
Heron Therapeutics Announces Acceptance of the Prior Approval Supplement Application for ZYNRELEF® Vial Access Needle ("VAN") PR Newswire -The U.S. Food and Drug Administration ("FDA") assigned a Prescription Drug User Fee Act ("PDUFA") goal date of September 23, 2024 ...
Heron Therapeutics Announces Prior Approval Supplement Submission to the FDA for ZYNRELEF® Vial Access Needle ("VAN") PR Newswire SAN DIEGO , May 29, 2024 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX) ("Heron" or the "Company"), a commercial-stage biotechn...